Hemoglobin levels
PD, anemia
ANEMIA
At baseline, the logEPO level was 0.77 ± 0.30 mIU/mL in the roxadustat group and 0.78 ± 0.31 mIU/mL in the ESA group. At week 24, the increase from baseline was 0.13 ± 0.42 mIU/mL and 0.78 ± 0.62 mIU/mL in the roxadustat and ESA groups. The difference between groups was -0.65 mIU/mL (95% CI, − 0.85 to − 0.45). Although the increase of logEPO levels in roxadustat group was much smaller than that in ESA group, no significant difference was observed in the improvement of anemia in PD patients between two groups. At week 24, hemoglobin levels increased 23.89 ± 17.87 g/L in roxadustat group and 19.73 ± 20.67 g/L in ESA group. The difference between groups was 4.16 g/L (95% CI, − 3.51 to 11.83). The percentage of patients with a hemoglobin level greater than or equal to 100 g/L but less than 120 g/L was 44.29% in the roxadustat group, and 47.22% in the ESA group in week 24 (Fig. Hemoglobin level and roxadustat dose in roxadustat group